Sterling Pharma Solutions, a UK-based CDMO, has entered a toll processing agreement with TPI Enterprises to manufacture Codeine Phosphate (CPO) for sale in the UK.
 
As part of the agreement, TPI Enterprises, one of three licensed poppy processors in Australia, will produce the narcotic raw material (NRM) at its site in Victoria, and Sterling will manufacture the CPO at its Dudley site near Newcastle, UK.
 
This agreement is part of TPI’s plan to expand its presence in the UK market.
 
Kevin Cook, chief executive officer of Sterling Pharma said, “We are delighted to be the partner of choice to support TPI Enterprises during this exciting period of growth. At Sterling, we have developed the infrastructure and capabilities to handle, manufacture and store controlled substances and we are well positioned to support this project.”
  
Jarrod Ritchie, chief executive officer at TPI Enterprises said, “The agreement will allow us to participate in the UK market and access a new, significant, and from a regulatory basis, previously inaccessible customer base. A combination of Sterling’s API production capability with our low cost raw material supply will greatly enhance customer options in the UK.”